Browse the evidence

GLP-1 receptor agonists and GLP-1/GIP biagonists reduce the expression of genes involved in lipogenesis in adipose tissue.

These drugs may help in managing fat storage by altering gene expression.

Biagonists or triagonists stimulating glucagon have a more potent effect to increase thermogenesis in adipose tissue.

These drugs may be particularly effective for enhancing energy expenditure.

The number of bariatric surgeries in Germany is significantly increasing.

Healthcare providers should be aware of the growing demand for bariatric surgery.

GLP-1 receptor agonism may decrease substance use and relapse.

GLP-1 receptor agonists may be beneficial in addiction treatment.

Dual agonists targeting GLP-1 and PYY3–36 may produce synergistic effects for weight loss.

Consider dual agonist therapies for enhanced weight loss efficacy.

Gastrointestinal side effects from tirzepatide are common but mild to moderate, with less than 5% treatment discontinuation.

Practitioners should be aware of potential mild gastrointestinal side effects when prescribing tirzepatide.

GLP-1ra users have similar postoperative outcomes following body contouring surgery compared to non-GLP-1ra controls.

Practitioners can consider GLP-1ra use as not adversely affecting postoperative outcomes in body contouring surgeries.

Postoperative cellulitis occurred less frequently among GLP-1ra users in matched cohorts.

GLP-1ra use may be associated with a lower risk of postoperative cellulitis.

Wound dehiscence is more prevalent among patients taking GLP-1ras for diabetes compared to those using it for weight loss.

Consideration of the indication for GLP-1ra use may be important in assessing surgical risk.

One-year discontinuation rates for GLP-1 receptor agonists can be as high as 74% in real-world studies.

Healthcare providers should be aware of the high discontinuation rates of GLP-1 RAs in real-world settings.

The distribution of protein intake (balanced vs unbalanced) did not influence myofibrillar protein synthesis rates.

The timing and distribution of protein intake may not be critical for maximizing muscle protein synthesis in young adults.

The percent kilocalories from carbohydrate was higher in the omnivorous group compared to the vegan group.

Omnivorous diets may provide a higher carbohydrate intake compared to vegan diets, which could influence overall energy balance.

The goal-achievement rate for glycaemic control decreased from 54.8% after 1 year of treatment to 19.4% 5 years later.

Practitioners should be aware that long-term glycaemic control may significantly decline.

The coefficient of failure (CoF) for glycaemic control was 0.123 ± 0.022%/year overall, with variations based on weight change.

Understanding the CoF can help in assessing long-term treatment effectiveness.

The hamstrings, iliopsoas, adductors, and tibialis anterior produced the largest downward acceleration about the center of mass.

Understanding these muscle contributions can help in designing rehabilitation programs focusing on these muscle groups.

Incretin combination therapies are being developed for the treatment of nonalcoholic fatty liver disease (NAFLD) in patients with diabetes.

Practitioners should consider the potential of incretin therapies for managing NAFLD in diabetic patients.

Obesity rates are high in high-income countries and are rapidly increasing in low- and middle-income countries.

Public health initiatives should focus on addressing obesity in both high-income and low-income countries.

The global consumption of unhealthy products, such as soft drinks and processed foods, continues to rise.

Efforts to promote healthier eating habits must address the rising consumption of unhealthy products.

The expansion of multinational food and beverage companies, or ‘Big Food’, is a key factor behind rising obesity rates and unhealthy consumption.

Regulatory measures may be needed to address the influence of 'Big Food' on public health.

There were no statistically significant differences in metabolic adaptations for 24 h, sleep, or resting expenditures.

This suggests that exercise may not lead to significant changes in metabolic rates during rest or sleep.

Reduction in HbA1c was not significantly different between the high- and low-dose intervention.

Both high and low doses of produce prescriptions may be equally effective for HbA1c reduction.

GIP receptor-modulating medications may cause weight loss.

GIP receptor-modulating therapies may be considered for obesity treatment, but further research is needed.

Diabetes mellitus is associated with nutritional and metabolic derangements that are often neglected in clinical assessments.

Healthcare professionals should prioritize nutritional assessments in diabetes management.

Sarcopenic diabetes is recognized as a distinct clinical condition that requires more awareness and research.

There is a need for increased focus on sarcopenic diabetes in clinical practice and research.